Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ranitil 300mg tablets
0103010T0BJABAC
|
Ranitil | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Rantec 300 tablets
0103010T0BGABAC
|
Rantec | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Ranzac 75mg tablets
0103010T0BKAAAP
|
Ranzac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Vivatak Indigestion Relief 75mg tablets
0103010T0BPAAAP
|
Vivatak | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zaedoc 150 tablets
0103010T0BFAAAA
|
Zaedoc | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 150mg effervescent tablets
0103010T0BBAFAI
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 150mg/10ml syrup
0103010T0BBAEAE
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 300mg effervescent tablets
0103010T0BBAGAJ
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 50mg/2ml solution for injection ampoules
0103010T0BBADAD
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 75 Dissolve tablets
0103010T0BBAJBK
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 75 Relief Dissolve tablets
0103010T0BBAKBK
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
|
Zantac 75 Relief tablets
0103010T0BBAIAP
|
Zantac | Ranitidine hydrochloride | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.